Harbor Advisory Corp MA Has $6.08 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Harbor Advisory Corp MA lowered its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 1.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 37,194 shares of the company’s stock after selling 531 shares during the quarter. Johnson & Johnson makes up approximately 2.8% of Harbor Advisory Corp MA’s investment portfolio, making the stock its 11th largest position. Harbor Advisory Corp MA’s holdings in Johnson & Johnson were worth $6,076,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Morton Brown Family Wealth LLC increased its position in Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after buying an additional 78 shares during the last quarter. Goodman Advisory Group LLC acquired a new position in Johnson & Johnson during the second quarter worth approximately $39,000. Cardinal Capital Management Inc. increased its position in Johnson & Johnson by 333.3% during the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after buying an additional 200 shares during the last quarter. First Bank & Trust increased its position in Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after buying an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LLC acquired a new position in Johnson & Johnson during the second quarter worth approximately $84,000. Institutional investors and hedge funds own 67.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Credit Suisse Group assumed coverage on Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective for the company. Sanford C. Bernstein reduced their price objective on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Raymond James reduced their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Citigroup boosted their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Finally, Bank of America reduced their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $181.75.

Johnson & Johnson Stock Down 0.5 %

NYSE JNJ opened at $168.74 on Friday. The business has a fifty day moving average price of $176.14 and a two-hundred day moving average price of $171.30. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a market capitalization of $441.17 billion, a PE ratio of 23.50, a PEG ratio of 3.28 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the prior year, the company earned $2.60 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is presently 62.95%.

Insiders Place Their Bets

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction on Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,707,775. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders sold 277,886 shares of company stock worth $48,550,549 over the last three months. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.